Cargando…

Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Impact of Chronic Kidney Disease on CYP3A4‐Mediated Metabolism of Saxagliptin

We characterized the impact of chronic kidney disease (CKD) on the cytochrome P450 (CYP) 3A4–mediated metabolism of saxagliptin to its metabolite, 5‐hydroxysaxagliptin, using a physiologically based pharmacokinetic (PBPK) model. A PBPK model of saxagliptin and its CYP3A4 metabolite, 5‐hydroxysaxagli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Butrovich, Morgan A., Tang, Weifeng, Boulton, David W., Nolin, Thomas D., Sharma, Pradeep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Physiologically Based Pharmacokinetic Modeling
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545133/ https://www.ncbi.nlm.nih.gov/pubmed/35247279 http://dx.doi.org/10.1002/jcph.2043

Ejemplares similares

Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6‐Mediated Drug‐Drug Interactions on Tramadol and O‐Desmethyltramadol Exposures via Allosteric and Competitive Inhibition
por: Long, Tao, et al.
Publicado: (2021)

Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling
por: Litjens, Carlijn H. C., et al.
Publicado: (2021)

Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug‐Drug Interaction Potential
por: Willmann, Stefan, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS‐CoV‐2 Infection: A Case Study With Imatinib
por: Adiwidjaja, Jeffry, et al.
Publicado: (2022)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Using Tofacitinib
por: Tse, Susanna, et al.
Publicado: (2020)

Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human
por: Wong, Yin Cheong, et al.
Publicado: (2019)

Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus
por: Melin, Johanna, et al.
Publicado: (2022)

Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment
por: Watanabe, Akiko, et al.
Publicado: (2021)

Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling
por: Størset, Elisabet, et al.
Publicado: (2014)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

Metabolism, Excretion, and Pharmacokinetics of [(14)C]‐Cefiderocol (S‐649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration
por: Miyazaki, Shiro, et al.
Publicado: (2019)

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism
por: Shi, Hui-Yan, et al.
Publicado: (2010)

Effect of renal impairment on the pharmacokinetics of exenatide
por: Linnebjerg, Helle, et al.
Publicado: (2007)

The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects
por: Stavros, Fiona, et al.
Publicado: (2010)

Effects of renal impairment on the pharmacokinetics of orally administered deferiprone
por: Fradette, Caroline, et al.
Publicado: (2016)

Population pharmacokinetic meta‐analysis of ramucirumab in cancer patients
por: O'Brien, Lisa, et al.
Publicado: (2017)

Pharmacokinetics of obinutuzumab in Chinese patients with B‐cell lymphomas
por: Zhai, John, et al.
Publicado: (2017)

Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment
por: Wu, Wanhong, et al.
Publicado: (2021)

Pharmacokinetics of Asfotase Alfa in Adult Patients With Pediatric‐Onset Hypophosphatasia
por: Pan, Wei‐Jian, et al.
Publicado: (2021)

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
por: Flint, Anne, et al.
Publicado: (2010)

Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non‐obese volunteers
por: Chairat, Kalayanee, et al.
Publicado: (2016)

Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain
por: Jonsson, E. Niclas, et al.
Publicado: (2016)

Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications
por: Hoglund, Richard M, et al.
Publicado: (2015)

Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?
por: Germovsek, Eva, et al.
Publicado: (2016)

Pharmacokinetics and Safety of Brexpiprazole Following Multiple‐Dose Administration to Japanese Patients With Schizophrenia
por: Ishigooka, Jun, et al.
Publicado: (2017)

Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy
por: Xu, Xiaoying, et al.
Publicado: (2016)

Pharmacokinetics and Safety of Intravenous Ferric Pyrophosphate Citrate: Equivalence to Administration via Dialysate
por: Marbury, Thomas, et al.
Publicado: (2022)

Opposite malaria and pregnancy effect on oral bioavailability of artesunate – a population pharmacokinetic evaluation
por: Kloprogge, Frank, et al.
Publicado: (2015)

ADAM, a hands‐on patient simulator for teaching principles of drug disposition and compartmental pharmacokinetics
por: Zuna, Ines, et al.
Publicado: (2017)

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment
por: Gupta, Neeraj, et al.
Publicado: (2016)

Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers
por: Pratt, Raymond D., et al.
Publicado: (2016)

Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin‐Mediated Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)

Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians
por: Hasunuma, Tomoko, et al.
Publicado: (2016)

Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent
por: Nguyen, Ashley, et al.
Publicado: (2021)

Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients With Pneumonia and Healthy Subjects
por: Kawaguchi, Nao, et al.
Publicado: (2022)

Monitoring vigabatrin in head injury patients by cerebral microdialysis: obtaining pharmacokinetic measurements in a neurocritical care setting
por: Shannon, Richard J, et al.
Publicado: (2014)

A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE‐3
por: Berger, Rolf M. F., et al.
Publicado: (2017)

Modeling Complex Pharmacokinetics of Long‐Acting Injectable Products Using Convolution‐Based Models With Nonparametric Input Functions
por: Gomeni, Roberto, et al.
Publicado: (2021)

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
por: Frost, Charles, et al.
Publicado: (2013)

Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets
por: Othman, Ahmed A, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_l57g6qal9d6adptd36dds7nsnq